BioPharmaceuticals, medical technology and generics

​The $100+ billion medical technology (med tech) industry is experiencing changes – pricing pressure that could threaten the innovation pipeline; increasingly stringent regulatory requirements; new value-based care models that require new value propositions; globalization complexities that call for new insights; and a shifting customer landscape that is likely to influence the buying process. Now med tech companies need to reconfigure their strategies and business models to deliver differentiated value and performance. 

The BioPharmaceutical marketplace is rapidly shifting and evolving. BioPharmaceutical organizations need to be nimble yet continue to grow revenue and market share even as industry dynamics propel increased focus on regulatory compliance, lower costs, innovation, and network flexibility.

Generics companies operating in the broader BioPharmaceutical market are being challenged by powerful dynamics including regulatory reforms, the Affordable Care Act, globalization, and the convergence of the Health Care and Life Sciences industries.